HARTFORD — At the advice of his acting public health commissioner, on Saturday Gov. Ned Lamont directed that Connecticut’s COVID-19 vaccine program follow recommendations for third doses to moderately or severely immunocompromised individuals.

On Friday the CDC (Centers for Disease Control and Prevention) released likewise recommendations.

On Thursday the U.S. Food and Drug Administration amended the emergency use authorization for both Moderna and Pfizer vaccines to allow for certain individuals with compromised immune systems to receive a third dose, according to Lamont’s office.

“Our vaccine providers stand ready to provide COVID vaccines in line with these updated recommendations,” Lamont said, noting the state Department of Public Health will be working in tandem with providers and the public.

“This recommendation will apply to a relatively small number of individuals in Connecticut,” Deidre Gifford, acting DPH commissioner said, “and we do not anticipate any challenges with adequate vaccine supply.”

“We have a broad and strong network of vaccine providers, including approximately 400 pharmacy locations alone, across the state, that are ready to administer additional COVID-19 vaccine doses in line with these recommendations,” she said.

According to Lamont’s office, people are considered moderately to severely immunocompromised if they are/have:

• Active treatment for solid tumor and hematologic malignancies
• Receipt of solid-organ transplant and taking immunosuppressive therapy
• Receipt of CAR-T-cell or hematopoietic stem cell transplant (within two years of transplantation or taking immunosuppression therapy)
• Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
• Advanced or untreated HIV infection
• Active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory.